Facts not fears should decide the future of telecoms network security in Europe,...
BARCELONA - Facts not fears should decide the future of telecoms network security in Europe, industry leaders and policy chiefs said this week, brushing off U.S. calls for a ban on Chinese vendors.
“You’re going to see a messy, essentially managed response that will probably vary in detail from country to country,” said Forrester analyst Frank Gillett. “In the end it’s about containing and managing the risk of Huawei, as well as any other vendor, but particularly Huawei.” “Let experts decide whether networks are safe or not. The U.S. security accusation of our 5G has no evidence, nothing,” Guo told the congress on Tuesday.
Strayer repeated U.S. assertions that the security issues with Huawei center around China’s 2017 National Intelligence Law, which states that Chinese “organizations and citizens shall, in accordance with the law, support, cooperate with, and collaborate in national intelligence work.” The Czech Republic and Poland, where a Huawei executive was arrested on espionage charges in January, have voiced concerns, while Britain has said it can manage any risks.
Washington has seen the Mobile World Congress as an opportunity to counter that and sent a delegation to brief governments there, they said.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. State Department says Europe is getting the message on HuaweiU.S. State Department says Europe is getting the message on the security risks posed by Huawei
Read more »
Europe Again Champions Intervention to Counter China’s Economic MightEurope’s struggle to keep up with China’s government coordination of business and economic might of the U.S. has prompted more European politicians to advocate interventionism.
Read more »
World’s best-selling drug costs five times more in U.S. than EuropeCritics accuse the maker of Humira of exploiting U.S. patent laws to keep competitors’ less expensive versions off the market. The company, AbbVie, says it’s balancing the need to keep the drug affordable to patients with the need to fund new drug development.
Read more »